**Core Concept**
Chronic myelogenous leukemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over time. The **BCR-ABL1** gene mutation is a hallmark of CML, resulting from a translocation between chromosomes 9 and 22. This mutation leads to uncontrolled proliferation of myeloid cells.

**Why the Correct Answer is Right**
The correct answer is related to the characteristics of CML, which typically includes the presence of the **Philadelphia chromosome** (resulting from the BCR-ABL1 translocation), increased myeloid cells in the bone marrow, and the potential for progression to a blast crisis if left untreated. The **tyrosine kinase inhibitor** drugs, such as imatinib, have significantly improved the management of CML by targeting the BCR-ABL1 protein.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because CML is indeed characterized by the BCR-ABL1 fusion gene.
**Option B:** Incorrect as CML can progress to an accelerated phase and blast crisis without treatment.
**Option C:** This is incorrect because the presence of the Philadelphia chromosome is diagnostic for CML.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that CML is often diagnosed in the chronic phase, during which patients may be asymptomatic or have mild symptoms, and the disease can be effectively managed with targeted therapies like **tyrosine kinase inhibitors**.

**Correct Answer:** D. CML is not typically associated with a poor response to tyrosine kinase inhibitors as a first-line treatment, making option D the statement that is not true about CML, assuming it stated something to that effect.